VIP - PCD patients
The population is composed of patients with plasma cell disorders (PCDs), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
The population is composed of patients with plasma cell disorders (PCDs), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Edmonton, Montreal, Ottawa, Toronto
-
Ethnic Origin
-
-
Health Status
-
Participants are diagnosed with plasma cell disorders and are also included if they have untreated monoclonal gammopathy of undetermined significance or smouldering myeloma.
Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.
-
Other Criteria
-
Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.
Participants are included if they are on active monotherapy with immunomodulators (IMID) or proteosome inhibitors (PI), on combination anti-CD38 plus PI therapy or combination anti-CD38 plus IMID therapy, or any other therapy.
-
Supplementary Information about selection criteria
-
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.
-
Number of Participants
-
378
-
Number of Participants with Biological Samples
-
378